Lobsor Pharmaceuticals Plans to Enter the U.S. Market with Treatment for Advanced Parkinson’s

Lobsor Pharmaceuticals Plans to Enter the U.S. Market with Treatment for Advanced Parkinson’s
The United States Patent and Trademark Office (USPTO) has approved a patent covering the composition and method of administration of a new levodopa replacement formulation for treating Parkinson’s disease. Lecigon was developed by Lobsor Pharmaceuticals to be the next-generation of Stalevo (marketed by Novartis), a widely used oral therapy for earlier stages of Parkinson’s disease. It consists of a gel containing a ... read more
Source: Parkinson’s News TodayPublished on 2019-03-26By Alice Melão